News | December 30, 2022
Claim against Dr. Reddy’s Laboratories dismissed over Revlimid in US
All claims against the company in the litigation have now been dismissed.
All claims against the company in the litigation have now been dismissed.
The new facility will be able to handle four times as many patients as the previous facility.
This ambitious anti-TB campaign, as part of IOCL’s CSR, aims to ensure early identification of presumptive TB and prompt diagnosis using high-sensitivity diagnostic tests at the doorstep
The current approval is first of the many fillings made by the company's CDMO partners from the flagship facility in Bangalore
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
For anaemia control in children (0-19 years) & resolves for Call to Action in this direction
A committee of two Joint Drugs Controllers has been constituted at CDSCO to monitor the process of inspection, reporting, and subsequent action to ensure compliance to the Drugs & Cosmetics Act, 1940
The company continue to develop this program for the WHO markets, thereby providing coverage and protection for more infants globally in time to come
Fulvestrant Injection, 250 mg/5 mL, has an estimated market size of US $71 million for twelve months ending Sep 2022 according to IQVIA
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
Subscribe To Our Newsletter & Stay Updated
